MedTrace Logo

Herpes Zoster Prevalence in Frailty Consultations

NCT02832986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1245

Last updated 2016-07-14

No results posted yet for this study

Summary

Herpes zoster and post herpetic pain are common causes of morbidity in the elderly. Herpes zoster is caused by reactivation of the virus varicella zoster of latent infection in sensory ganglia. The acute phase of herpes zoster usually occurs ≤ 30 days after rash onset. However, the most common complication of herpes zoster is the post herpetic pain, which is usually defined as a persistent chronic pain for ≥ 3 months after rash onset. The risk of herpes zoster in life is 25-30%, but this figure rises to 50% among those aged ≥ 85 years. Similarly, the risk of experiencing post herpetic pain increases with age.

Despite treatment with antiviral drugs, post herpetic pain has been reported in 10-20% of all patients with herpes zoster, but its incidence increases significantly in elderly patients over 60 years. It can be particularly harmful when it occurs on a particular field, elderly multiple pathologies, fragile and with multiple treatment. In this context of decompensation "cascade" greatly exacerbate the impact of the initial local disease. Ophthalmologic involvement is rare but clinically worrisome and generates significant costs.

Conditions

  • Herpes Zoster

Interventions

OTHER

Medical Questionary

The medical questionary will contain : * Date of initial infection by Herpes zoster * Localisation * Severity * Presence of postherpetic pain * Postherpetic pain Intensity * Postherpetic pain duration * Antiviral treatment * History of chronic pathologies * Concomitant treatment

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Bruno VELLAS, MD · University Hospital of Toulouse

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832986 on ClinicalTrials.gov